Drugs / Akt Inhibitor MK2206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01776008 | Jan 2013 → May 2015 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Akt Inhibitor MK2206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01776008 ↗ |
| Action | Inhibit | “MK-2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01776008 ↗ |
| Route | Oral | “Akt inhibitor MK-2206 orally (PO)” NCT01776008 ↗ |